文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

床旁超声在院前非创伤性急性呼吸困难患者管理中的作用:系统评价与荟萃分析

Contribution of point-of-care ultrasound in the prehospital management of patients with non-trauma acute dyspnea: a systematic review and meta-analysis.
PubMed 文献 · Eur J Emerg Med · 2024-12-03
一句话结论院前非创伤性急性呼吸困难患者使用床旁超声可行,对急性心力衰竭诊断贡献大,并可能改变治疗,但缺乏高级别证据。

该系统评价与荟萃分析检索7个数据库及灰色文献,纳入1995年1月至2023年11月发表的英文研究,共23项,评估床旁超声对院前非创伤性急性呼吸困难患者在可行性、诊断、治疗、预后、转诊和转运方式等方面的贡献。肺超声可行性中等至优秀,心脏超声可行性差至一般,检查中位时间不足5分钟;床旁超声改善诊断识别,对气胸诊断准确性优秀(敏感性100%、特异性100%),对急性心力衰竭很好(敏感性71-100%、特异性72-95%),对肺炎良好(敏感性88%、特异性59%),对胸腔积液中等(敏感性26-53%、特异性83-92%)。治疗在11%至54%的患者中被修改,对预后无显著影响,对转诊和转运方式的贡献分别为51%和25%。证据支持院前使用床旁超声管理非创伤性急性呼吸困难,尤其在肺超声诊断急性心力衰竭方面,但缺乏高级别证据。

要点

  • 院前肺超声可行性中等至优秀,心脏超声可行性差至一般;检查中位时间不足5分钟(6项研究)。
  • 床旁超声对气胸诊断准确性优秀(敏感性100%、特异性100%,2项研究),对急性心力衰竭很好(敏感性71-100%、特异性72-95%,8项研究)。
  • 床旁超声对肺炎诊断良好(敏感性88%、特异性59%,1项研究),对胸腔积液诊断中等(敏感性26-53%、特异性83-92%,2项研究)。
  • 床旁超声使11%至54%的患者治疗被修改(7项研究),对预后无显著影响(2项研究)。
  • 床旁超声对患者转诊和转运方式的贡献分别为51%(4项研究)和25%(3项研究)。

适用人群与场景

  • 任何年龄的非创伤患者,在院前环境中因急性呼吸困难接受管理并接受床旁超声检查。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析;共纳入23项研究;检索7个数据库及灰色文献,英文研究,发表时间1995年1月至2023年11月。
  • 偏倚风险评估:3项中等风险、18项严重风险、2项关键风险研究。
  • 可行性:3项研究报道肺超声可行性中等至优秀,3项研究报道心脏超声可行性差至一般;6项研究报道床旁超声检查中位时间不足5分钟。
  • 诊断识别:7项研究报道床旁超声改善诊断识别。
  • 诊断准确性:气胸敏感性100%、特异性100%(2项研究);急性心力衰竭敏感性71-100%、特异性72-95%(8项研究);肺炎敏感性88%、特异性59%(1项研究);胸腔积液敏感性26-53%、特异性83-92%(2项研究)。
  • 治疗修改:11%至54%的患者治疗被修改(7项研究)。
  • 预后:床旁超声对患者预后无显著影响(2项研究)。
  • 转诊与转运:床旁超声对患者转诊的贡献为51%(4项研究),对转运方式的贡献为25%(3项研究)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析。
  • 原文指出缺乏高级别证据且需要高级别证据。
  • 局限:纳入研究偏倚风险为3项中等风险、18项严重风险、2项关键风险;缺乏高级别证据。

对床旁实践的改变

  • 证据支持在院前环境中使用床旁超声管理非创伤性急性呼吸困难,在可行性、总体诊断贡献方面,尤其是肺超声用于急性心力衰竭诊断。
  • 床旁超声似乎具有治疗贡献。
  • 证据不足以支持使用床旁超声诊断肺炎、胸腔积液、气胸、慢性阻塞性肺疾病或哮喘急性发作,也不支持其预后、患者转诊和转运方式方面的贡献。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Acute dyspnea is a common symptom whose management is challenging in prehospital settings. Point-of-care ultrasound (POCUS) is increasingly accessible because of device miniaturization. To assess the contribution of POCUS in the prehospital management of patients with acute nontraumatic dyspnea, we performed a systematic review on nontrauma patients of any age managed in the prehospital setting for acute dyspnea and receiving a POCUS examination. We searched seven databases and gray literature for English-language studies published from January 1995 to November 2023. Two independent reviewers completed the study selection, data extraction, and risk of bias assessment. The primary outcome was the assessment of the contribution of POCUS to feasibility, diagnostic, therapeutic, prognosis, patient referral, and transport vector modification. Twenty-three studies were included. The risk of bias assessment identified 3 intermediate-risk, 18 serious-risk, and 2 critical-risk studies. Three studies reported moderate to excellent feasibility for lung POCUS, and three studies reported poor to mediocre feasibility for cardiac POCUS. The median duration of the POCUS examination was less than 5 minutes (six studies). POCUS improved diagnostic identification (seven studies). The diagnostic accuracy of POCUS was excellent for pneumothorax (sensitivity = 100%, specificity = 100%, two studies), very good for acute heart failure (sensitivity = 71-100%, specificity = 72-95%, eight studies), good for pneumonia (sensitivity = 88%, specificity = 59%, one study), and moderate for pleural effusion (sensitivity = 26-53%, specificity = 83-92%, two studies). Treatment was modified in 11 to 54% of the patients (seven studies). POCUS had no significant effect on patient prognosis (two studies). POCUS contributed to patient referrals and transport vectors in 51% (four studies) and 25% (three studies) of patients, respectively. The evidence supports the use of POCUS for managing acute nontraumatic dyspnea in the prehospital setting in terms of feasibility, overall diagnostic contribution, and, particularly, lung ultrasound for acute heart failure diagnosis. Moreover, POCUS seems to have a therapeutic contribution. There is not enough evidence supporting the use of POCUS for pneumonia, pleural effusion, pneumothorax, chronic obstructive pulmonary disease, or asthma exacerbation diagnosis, nor does it support prognostic, patient referral, and transport vector contribution. A high level of evidence is lacking and needed.

来源:Eur J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Taheri O, Samain J, Mauny F, et al. Contribution of point-of-care ultrasound in the prehospital management of patients with non-trauma acute dyspnea: a systematic review and meta-analysis. Eur J Emerg Med. 2024. PMID: 39630617. doi:10.1097/MEJ.0000000000001205

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。